US 9115371
Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
granted A61KA61K2239/49A61K31/4025
Quick answer
US patent 9115371 (Reduction of TGF beta signaling in myeloid cells in the treatment of cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Aug 25 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2239/49, A61K31/4025, A61K31/5377, A61K31/7088